Abstracts tagged "Biologicals"

Abstract Number: 2519 • ACR Convergence 2025
A Disproportionality Analysis of FDA Adverse Event Reporting System (FAERS) Events for Avacopan
Shiamak Cooper¹, Asim Khanfar², Yousef al-mabrouk³, Omar Hamdan⁴ and Anthony Ocon⁵, ¹Rochester General Hospital, Irondequoit, NY, ²Rochester General Hospital, Rochester, NY, ³Prince Hanza Hospital, Amman, Jordan, ⁴University of Jordan, Az-Zarqa, Jordan, ⁵Rochester Regional Health, Fairport, NY
Background/Purpose: Avacopan, a C5a receptor inhibitor, is used as an adjunctive treatment for ANCA-associated vasculitis. Previous studies have highlighted its efficacy in reducing glucocorticoid use…
Abstract Number: 2358 • ACR Convergence 2025
Bimekizumab Demonstrated Early and Sustained Efficacy Regardless of Baseline Characteristics in Patients with Active Psoriatic Arthritis: Pooled Post Hoc Results up to 1-Year from Two Phase 3 Studies
Lihi Eder¹, Philip J. Mease², Iain McInnes³, M. Elaine Husni⁴, Mitsumasa Kishimoto⁵, Barbara Ink⁶, Rajan Bajracharya⁶, Jason Coarse⁷ and Fabian Proft⁸, ¹University of Toronto, Toronto, ON, Canada, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³University of Glasgow, Glasgow, United Kingdom, ⁴Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁵Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, ⁶UCB, Slough, England, United Kingdom, ⁷UCB, Morrisville, NC, ⁸Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL‑17A, has demonstrated clinical efficacy and safety to 3 years…
Abstract Number: 2203 • ACR Convergence 2025
Maternal and Fetal Outcomes Associated with IL-17 Inhibitor Exposure During Pregnancy in Patients with Seronegative Arthritis: A Case Series of Nine
Arshdeep Waring¹, Sofia Rieger-Torres², Jeremiah Tan³, Viktoria Pavlova⁴ and Neda Amiri⁵, ¹University of British Columbia, Abbotsford, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴McMaster University, Ancaster, ON, Canada, ⁵University of British Columbia, North Vancouver, BC, Canada
Background/Purpose: Interleukin-17 (IL-17) inhibitors, such as ixekizumab and secukinumab, are increasingly used in the treatment of seronegative inflammatory arthritis, including psoriatic arthritis and axial spondyloarthritis.…
Abstract Number: 1656 • ACR Convergence 2025
Risk of Serious Infection associated with non-TNF biologic initiation after Anti-TNF Use in Older Adults with Rheumatoid Arthritis
Jiha Lee¹, Sofia Pedro² and Kaleb Michaud³, ¹University of Michigan, Ann Arbor, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: In older adults with rheumatoid arthritis (RA), anti-TNF therapies are typically used as first-line biologic treatment. However, many patients require a switch to non-TNF…
Abstract Number: 1464 • ACR Convergence 2025
Incidence of Major Adverse Cardiovascular Events (MACE) in Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis Patients With and Without Cardiovascular Risk Factors Treated With Secukinumab: Five-Year Safety Data from the Real-World SERENA Study
Uta Kiltz¹, Petros Sfikakis², Andreas Bounas³, Nicola Gullick⁴, Eric LESPESSAILLES⁵, Jan Brandt-Juergens⁶, Rasho Rashkov⁷, Cynthia Vizcaya⁸, Andreas Clemens⁸, Lara Gómez⁹, Kim Hoyt¹⁰, Weibin Bao¹¹ and Karl Gaffney¹², ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²NKUA - SCHOOL OF MEDICINE, Athens, Greece, ³‘OLYMPION’, General Clinic of Patra, Patra, Greece, ⁴Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK, Coventry, United Kingdom, ⁵University Hospital of Orléans, Orleans, France, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Clinic of Rheumatology, University Hospital St. Ivan Rilski, Sofia, Bulgaria, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Farmaceutica, Madrid, Spain, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹²Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom
Background/Purpose: Patients with psoriasis (PsO), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are at increased risk of major adverse cardiovascular events (MACE) due to systemic…
Abstract Number: 1368 • ACR Convergence 2025
Thrombocytosis Predicts Response to Biologic and Targeted Synthetic DMARDs in Rheumatoid Arthritis: Data from the Korean KOBIO Registry
Se Hee Kim¹ and kyung-Ann Lee², ¹Kyung Hee University College of Medicine, Seoul, Republic of Korea, ²Soonchunhyang University Hospital Seoul: Soonchunhyang University Hospital, Seoul, Republic of Korea
Background/Purpose: This study aimed to evaluate the clinical characteristics of thrombocytosis, its relationship with disease activity and joint involvement, and its influence on the effectiveness…
Abstract Number: 1164 • ACR Convergence 2025
Effect of TNF Inhibitors on the Postprandial Glucose Homeostasis Molecules: Amylin, Gastric Inhibitory Polypeptide, and Pancreatic Polypeptide in Rheumatic Patients
José Carlos García-Hernández¹, Iván Ferraz Amaro², Marta Hernández Díaz², Ana Isabel Rodríguez Vargas¹ and Federico Díaz González¹, ¹Hospital Universitario de Canarias, Santa Cruz De Tenerife, Canarias, Spain, ²Servicio Canario de Salud, La Laguna, Canarias, Spain
Background/Purpose: The effect of systemic TNF inhibition on postprandial glucose homeostasis, a parameter associated with cardiovascular health, remains unclear. This study aims to evaluate the…
Abstract Number: 0987 • ACR Convergence 2025
S-4321, a novel dual-cell bifunctional PD-1:FcγRIIb selective agonist antibody for autoimmune disease, maintains expression of PD-1 on target cells and enhances inhibitory receptor expression on T cells in vivo
Julia Manasson¹, Michael Cianci², Minasri Borah², Stephanie Grebinoski², Joshua Vitlip², Stephen Lutz², Ishan Sharma², Elliott Wittenberg², Allison Colthart², Samuel Perry², Maria Cecilia Ramello², Chelsea R. Parker Harp², Jyothsna Visweswaraiah², Ryan Peckner², Alex Pellerin², Heather Vital³, John Sundy⁴, Nathan Higginson-Scott², Kevin L. Otipoby² and Daniela Cipolletta², ¹Seismic Therapeutic, New York, NY, ²Seismic Therapeutic, Watertown, MA, ³Seismic Therapeutic, Lexington, MA, ⁴Seismic Therapeutic, Durham, NC
Background/Purpose: S-4321 is a novel antibody that agonizes the inhibitory PD-1 checkpoint receptor on T cells without competing for binding with its natural ligand, PD-L1,…
Abstract Number: 0558 • ACR Convergence 2025
Early Systemic and Skin Pharmacodynamic Effects of Icotrokinra in Participants with Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, ICONIC-LEAD Study
Julianty Angsana¹, Marta Polak¹, Sharan Nischal¹, Elizabeth Chen¹, Deepika Balakrishna², Ching-Heng Chou¹, Christopher Sisk³, Lynn Tomsho¹, Arun Kannan¹, Cynthia DeKlotz¹, Megan Miller⁴, Joseph Cafone³, Paul Newbold¹, Ya-Wen Yang¹, Monica Leung¹, Dawn Waterworth¹, Nina Sabins¹, Anna Perillo⁵, Andreas Pinter⁶ and Robert Bissonnette⁷, ¹Johnson & Johnson, San Diego, CA, USA, San Diego, CA, ²Johnson & Johnson, San Diego, CA, USA, San Diego, USA, ³Johnson & Johnson, San Diego, CA, USA, San Diego, CA, CA, ⁴Johnson & Johnson, San Diego, CA, USA, San Diego, CA,, CA, ⁵The Rockefeller University, New York, NY, USA, New York, NY, ⁶Goethe University Frankfurt, Frankfurt, Germany, Frankfurt, Germany, ⁷Innovaderm Research, Montreal, QC, Canada, Montreal, QC
Background/Purpose: Icotrokinra (ICO), a first-in-class targeted oral peptide that blocks the interleukin (IL)-23R and inhibits IL-23 pathway signaling, is being evaluated in the phase 3…
Abstract Number: 0503 • ACR Convergence 2025
Impact of Olokizumab on Pain in Rheumatoid Arthritis: a Meta-analysis
Andrey E. Karateev¹, Sofia Kuzkina², Alina Egorova³ and Elena Y. Polishchuk¹, ¹V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ²R-Pharm, Moscow, Russia, ³R-Pharm JSC, Moscow, Russia
Background/Purpose: Pain is one of the most debilitating symptoms of rheumatoid arthritis (RA) and a major contributor to reduced quality of life. Persistent joint pain…
Abstract Number: 0251 • ACR Convergence 2025
Impact of Mepolizumab on Idiopathic Hypereosinophilic Syndromes: Preliminary Analysis of a Monocentric Retrospective Cohort
Jacopo Mora¹, Francesca Regola¹, Paola Toniati², Giulia Fontana¹, Alessia Gatti¹, Ilaria Cavazzana³ and Franco Franceschini⁴, ¹Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili and University of Brescia, Brescia, Lombardia, Italy, ²Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili of Brescia, Brescia, Lombardia, Italy, ³Rheumatology and Clinical Immunology Unit, Clinical and Experimental Sciences Department, ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Brescia, Italy, Brescia, Lombardia, Italy, ⁴University of Brescia, Brescia, Brescia, Italy
Background/Purpose: Idiopathic hypereosinophilic syndromes (iHES) are a group of disorders characterized by persistent eosinophilia and eosinophil-mediated organ damage. Mepolizumab, an anti-interleukin-5 monoclonal antibody, has proven…
Abstract Number: 2477 • ACR Convergence 2025
Current treatment Strategies in Systemic Sclerosis- Interstitial Lung Disease Patients: Real-World Insights from the EUSTAR Cohort (CP138)
Corrado Campochiaro¹, Marie-Elise Truchetet², Madelon Vonk³, Giacomo De Luca⁴, Giovanna Cuomo⁵, Lidia P Ananieva⁶, Eric Hachulla⁷, Vanessa Smith⁸, Ana Maria Gheorghiu⁹, Radim Bečvář¹⁰, Patricia E. Carreira¹¹, Nicolas Hunzelmann¹², Daniel Furst¹³, Vera Ortiz-Santamaria¹⁴, Francesco Del Galdo¹⁵, Marco Matucci-Cerinic¹⁶ and Anna-Maria Hoffmann-Vold¹⁷, ¹IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ²Bordeaux University Hospital, Bordeaux, France, ³Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Milan, Italy, ⁵Department of Precision Medicine, University Hospital Luigi Vanvitelli, Naples, Italy, Naples, Italy, ⁶A Nasonova Institute of Rheumatology, Moscow, Russian Federation, Moscow, Russia, ⁷University of Lille, LILLE, France, ⁸Ghent University Hospital, Gent, Belgium, ⁹Spitalul Clinic Dr. Ion Cantacuzino, Bucharest, Romania, ¹⁰Department of Internal Medicine, Charles University,, Prague, Czech Republic, ¹¹Hospital Universitario ¹² de Octubre, Madrid, Spain, ¹²Department of Dermatology and Venereology, University Hospital Cologne, Cologne, Germany, ¹³Southern California Scleroderma and Rheumatology Center, Los Angeles, CA, ¹⁴HOSP. GENERAL DE GRANOLLERS, Barcelona, Spain, ¹⁵University of Leeds, Leeds, United Kingdom, ¹⁶University San Raffaele Milano, Milano, Milan, Italy, ¹⁷Oslo University Hospital, Oslo, Norway
Background/Purpose: The therapeutic landscape for systemic sclerosis- interstitial lung disease (SSc-ILD) has rapidly evolved over the past decade, with increasing adoption of immunosuppressive (IST) and…
Abstract Number: 2354 • ACR Convergence 2025
ChatGPT or SPSS? A comparison between AI-based and Traditional Statistical Analysis of Longitudinal Inflammatory Marker Data in Spondyloarthritis
José Miguel Sequí-Sabater¹, Pablo Beltrán Martin-Lorente², Sonia Pastor Navarro³, Maria del Carmen Lopez Gonzalez⁴, Maria Sanchez-Wonenburger⁵, DESAMPARADOS CASADO POVEDA³ and Anna Martínez Cristóbal⁶, ¹La Ribera University Hospital, Rheumatology Department, Gandía, Spain, ²Universidad Católica de Valencia "San Vicente Mártir", Valencia, Comunidad Valenciana, Spain, ³La Ribera University Hospital, Rheumatology Department, Valencia, Comunidad Valenciana, Spain, ⁴La Ribera University Hospital, Rheumatology Department, Cullera, Comunidad Valenciana, Spain, ⁵Hospital Universitario de La Ribera, València, Comunidad Valenciana, Spain, ⁶La Ribera University Hospital, Rheumatology Department, Alzira, Comunidad Valenciana, Spain

Background/Purpose: While traditional analysis relies on statistical software such as SPSS, emerging tools like ChatGPT introduce the possibility of performing statistical tests, interpreting results, and…
Abstract Number: 2143 • ACR Convergence 2025
Ruxolitinib for Refractory sJIA/AOSD: A Single Center Case Series
Jacqueline Madison¹, Andrew Grim² and Janna Shim³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan Medicine, Ann Arbor, MI, ³Midwestern University Chicago College of Osteopathic Medicine, Downers Grove
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still’s disease (AOSD) are rare, chronic, autoinflammatory diseases distinct from other forms of chronic inflammatory arthritis. Potential…
Abstract Number: 1629 • ACR Convergence 2025
Real-World Effectiveness of Interleukin-6 Receptor Inhibitors Compared to Methotrexate in Steroid-Refractory Frail Patients with Polymyalgia Rheumatica
Sebastian E Sattui¹, Christian Dejaco², Kerri Ford³, Stefano Fiore⁴, Sebastian H Unizony⁵, Fenglong Xie⁶ and Jeffrey Curtis⁷, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medical University of Graz, Department of Rheumatology, Graz, Austria; Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, ³Sanofi, Cambridge, MA, ⁴Sanofi, Morristown, NJ, ⁵Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁶The University of Alabama at Birmingham, Birmingham, AL, ⁷Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: A previous post hoc analysis of frail (defined by claims-based frailty index [CFI] ≥0.2) patients with PMR on second line (2L) and 3L treatment…

« Previous Page
1
…
8
9
10
11
12
…
67
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].